Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$21.95
-1.4%
$19.37
$8.89
$26.66
$967.65MN/A1.17 million shs306,328 shs
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$3.55
-2.5%
$3.52
$1.60
$13.44
$270.32M1.14790,017 shs802,422 shs
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$7.31
+1.4%
$7.07
$5.47
$10.14
$1.07B1.73614,672 shs1.32 million shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$15.01
+2.0%
$12.63
$9.98
$42.70
$993.95M1.481.85 million shs2.14 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
0.00%+13.98%+10.20%+66.12%+2,225,999,900.00%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
0.00%+7.06%+5.20%+4.60%-72.73%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
0.00%+3.89%+0.98%+11.27%+25.17%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
0.00%+22.58%+16.93%-9.48%-64.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$21.95
-1.4%
$19.37
$8.89
$26.66
$967.65MN/A1.17 million shs306,328 shs
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$3.55
-2.5%
$3.52
$1.60
$13.44
$270.32M1.14790,017 shs802,422 shs
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$7.31
+1.4%
$7.07
$5.47
$10.14
$1.07B1.73614,672 shs1.32 million shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$15.01
+2.0%
$12.63
$9.98
$42.70
$993.95M1.481.85 million shs2.14 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
0.00%+13.98%+10.20%+66.12%+2,225,999,900.00%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
0.00%+7.06%+5.20%+4.60%-72.73%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
0.00%+3.89%+0.98%+11.27%+25.17%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
0.00%+22.58%+16.93%-9.48%-64.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
2.69
Moderate Buy$24.4411.36% Upside
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.18
Buy$12.56253.68% Upside
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
2.50
Moderate Buy$12.0064.16% Upside
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.24
Hold$22.4449.48% Upside

Current Analyst Ratings Breakdown

Latest CATX, MDXG, TNDM, and BBNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/3/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$10.00
10/2/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$11.00
10/1/2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetNeutralBuy$18.00 ➝ $26.00
10/1/2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy$18.00 ➝ $26.00
9/29/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00
9/27/2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
9/27/2025
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/27/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/22/2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$21.00 ➝ $28.00
9/19/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$10.00
9/15/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$11.00
(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$65.12M14.65N/AN/A($5.72) per share-3.84
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$1.45M181.81N/AN/A$4.30 per share0.83
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$348.88M3.10$0.34 per share21.76$1.31 per share5.58
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$940.20M1.08N/AN/A$4.01 per share3.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
-$54.76MN/A0.00N/AN/AN/AN/AN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$79.28MN/A0.00N/AN/A-7,688.50%-33.37%-28.44%11/11/2025 (Estimated)
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$42.42M$0.2134.8122.84N/A8.84%23.03%17.09%10/29/2025 (Estimated)
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$96.03M-$3.09N/AN/AN/A-20.51%-65.40%-13.87%11/6/2025 (Estimated)

Latest CATX, MDXG, TNDM, and BBNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2025Q3 2025
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$0.07N/AN/AN/A$94.74 millionN/A
8/6/2025Q2 2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.40-$0.48-$0.08-$0.78$238.39 million$240.68 million
7/30/2025Q2 2025
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$0.06$0.10+$0.04$0.06$90.79 million$98.61 million
7/29/2025Q2 2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/AN/AN/AN/AN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/AN/A
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
N/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/A
14.68
13.79
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
0.01
15.09
15.09
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
0.08
4.39
3.90
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.32
2.44
1.88

Institutional Ownership

CompanyInstitutional Ownership
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
54.66%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
79.15%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/A

Insider Ownership

CompanyInsider Ownership
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.52%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
1.70%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
29443.47 millionN/AN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
7074.26 million71.65 millionOptionable
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
870147.96 million145.44 millionOptionable
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2,65067.57 million66.29 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Beta Bionics stock logo

Beta Bionics NASDAQ:BBNX

$21.95 -0.31 (-1.39%)
As of 04:00 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Perspective Therapeutics stock logo

Perspective Therapeutics NYSEAMERICAN:CATX

$3.55 -0.09 (-2.47%)
Closing price 04:10 PM Eastern
Extended Trading
$3.57 +0.02 (+0.45%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

MiMedx Group stock logo

MiMedx Group NASDAQ:MDXG

$7.31 +0.10 (+1.39%)
Closing price 04:00 PM Eastern
Extended Trading
$7.24 -0.07 (-1.03%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Tandem Diabetes Care stock logo

Tandem Diabetes Care NASDAQ:TNDM

$15.01 +0.30 (+2.04%)
Closing price 04:00 PM Eastern
Extended Trading
$14.86 -0.15 (-1.03%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.